...
首页> 外文期刊>Experimental and clinical endocrinology and diabetes: Official journal, German Society of Endocrinology [and] German Diabetes Association >Expression Changes of Mitogen-activated Protein Kinase Phosphatase-1 (MKP-1) in Myocardium of Streptozotocin-Induced Diabetic Rats.
【24h】

Expression Changes of Mitogen-activated Protein Kinase Phosphatase-1 (MKP-1) in Myocardium of Streptozotocin-Induced Diabetic Rats.

机译:链脲佐菌素诱导的糖尿病大鼠心肌中丝裂素活化蛋白激酶磷酸酶-1(MKP-1)的表达变化。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

MAP Kinase Phosphatase-1 (MKP-1) is a dual specific phosphatase selective for MAP kinases, and was believed to implicate in the development of cardiac hypertrophy. However, whether MKP-1 is involved in the pathogenesis of diabetic cardiomyopathy is still unknown. We employed streptozotocin (STZ)-induced diabetic Sprague-Dawley rats to study the alteration of the MKP-1 expressions in the left ventricular myocardium in diabetic and normal groups by immunohistochemistry and real-time quantitative reverse transcription-polymerase chain reaction. The weight, blood sugar and urine sugar were measured before and after model induction in both control and diabetic groups. Changes of heart ultrastructure were analyzed by using transmission electron microscopy. The data of weight, blood sugar and urine sugar indicated no significant difference between the two groups before animal model induction. Eight weeks after the induction of diabetes, the differences between the control and the diabetic groups in weight, blood sugar and urine sugar were significant ( P<0.01). When compared with control, diabetic myocardium ultrastructural changes included myofibrillar disarrangements, mitochondria disruption, and increase in nuclear membrane invaginations. A significant decrease of MKP-1 expression was observed in the diabetic rats' myocardium ( P<0.01). Our study provides experimental evidences that hyperglycemia could damage myocardial ultrastructure. Moreover, we provided first evidence that down-regulation of cardioprotective peptide MKP-1, the MAPK pathway negative regulator, in myocardium of streptozotocin-induced diabetic rats, which may contribute to the deterioration of cardiac function and lead to diabetic cardiomyopathy.
机译:MAP激酶磷酸酶1(MKP-1)是对MAP激酶具有选择性的双重特异性磷酸酶,被认为与心脏肥大的发生有关。然而,MKP-1是否参与糖尿病性心肌病的发病机制仍是未知的。我们采用链脲佐菌素(STZ)诱导的糖尿病Sprague-Dawley大鼠通过免疫组织化学和实时定量逆转录聚合酶链反应研究了糖尿病组和正常组左心室心肌MKP-1表达的变化。在对照组和糖尿病组中,在模型诱导之前和之后测量体重,血糖和尿糖。使用透射电子显微镜分析心脏超微结构的变化。动物模型诱导前,体重,血糖和尿糖数据表明两组之间无显着差异。糖尿病诱发后八周,对照组和糖尿病组在体重,血糖和尿糖方面存在显着差异(P <0.01)。与对照组相比,糖尿病心肌的超微结构变化包括肌原纤维排列紊乱,线粒体破坏和核膜内陷增加。糖尿病大鼠心肌MKP-1表达明显降低(P <0.01)。我们的研究提供了高血糖可能会损害心肌超微结构的实验证据。此外,我们提供了第一个证据,证明链脲佐菌素诱发的糖尿病大鼠心肌中的心肌保护肽MKP-1(MAPK途径负调节剂)下调,这可能导致心脏功能恶化并导致糖尿病性心肌病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号